Last updated on April 2018

Study of SyB C-1101 in Patients With Myelodysplastic Syndrome


Brief description of study

To assess tolerability of SyB C-1101 when administered orally BID for 21 days followed by a 7-day observation period in patients with recurrent/relapsed or refractory myelodysplastic syndrome in order to determine a recommended dose (RD). To assess safety, efficacy and pharmacokinetics.

Clinical Study Identifier: NCT03495167

Find a site near you

Start Over

Research Site

Kyoto, Japan
5.71miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.